Cargando…

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation

PURPOSE OF REVIEW: Inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) with denosumab is an effective treatment in a number of conditions including osteoporosis where suppression of bone resorption is desired. However, denosumab discontinuation is associated with rebound increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Albert S., Girgis, Christian M., McDonald, Michelle M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Osteoimmunology (A Pettit and J Charles, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718877/ https://www.ncbi.nlm.nih.gov/pubmed/36201122 http://dx.doi.org/10.1007/s11914-022-00756-5

Ejemplares similares

CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple
por: Hume, David A., et al.
Publicado: (2022)

Vitamin D Regulation of Immune Function
por: Bikle, Daniel D
Publicado: (2022)

Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease
por: Tseng, Hsu-Wen, et al.
Publicado: (2022)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
por: Fu, Qiang, et al.
Publicado: (2023)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease
por: Anık, Ahmet
Publicado: (2022)

Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri‐implant bone loss
por: Li, Xianqi, et al.
Publicado: (2016)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Čulić, Viktor, et al.
Publicado: (2021)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
por: Jähn-Rickert, Katharina, et al.
Publicado: (2020)

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Recoupling the Cardiac Nitric Oxide Synthases: Tetrahydrobiopterin Synthesis and Recycling
por: Alkaitis, Matthew S., et al.
Publicado: (2012)

Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society
por: Kim, Bu Kyung, et al.
Publicado: (2021)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Reply to Čulić et al—COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Fardman, Alexander, et al.
Publicado: (2021)

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission
por: Stuckey, Ruth, et al.
Publicado: (2022)

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

A Long, Happy, Healthy but Uncomfortable Life?
Publicado: (1999)

Should You Complete Your Course of Antibiotics?
Publicado: (1999)

Should Everyone Expect to Be a Top Chap?
Publicado: (1999)

The Management of Cancer Timing and the Two Week Rule
Publicado: (2000)

Postcode or National (World) Governance, and the Art of Medicine
Publicado: (2000)

Do We Need a Real Health Service?
Publicado: (2000)

Public Health: Beware the Lobby and Listen to the Generalist
por: Coemgenus,
Publicado: (2000)

Communication and Complaints
Publicado: (1999)

Clinical Governance: Expect Not the Best but the Ideal
Publicado: (1999)

Money Is Only a Small Part of the Answer
Publicado: (2000)

Head rebound test in the clinical neurological examination of veterinary patients: a case example and discussion of Stewart and Holmes’ rebound phenomenon
por: Santifort, Koen M.
Publicado: (2023)

Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases
por: Upfill‐Brown, Alexander, et al.
Publicado: (2019)

Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes
por: Allan, Louise M.
Publicado: (2019)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tpc3r4poh0g019lmame44545h1